{"id":33598,"date":"2025-05-16T13:00:22","date_gmt":"2025-05-16T05:00:22","guid":{"rendered":"https:\/\/flcube.com\/?p=33598"},"modified":"2025-05-16T13:00:22","modified_gmt":"2025-05-16T05:00:22","slug":"rznomics-and-eli-lilly-collaborate-on-rna-editing-therapies-for-sensorineural-hearing-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33598","title":{"rendered":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss"},"content":{"rendered":"\n

South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY<\/a>). The partnership aims to utilize Rznomics’ proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.<\/p>\n\n\n\n

Focus on Sensorineural Hearing Loss<\/strong>
The collaboration will concentrate on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research in accordance with jointly approved research plans, while Lilly will take over further development and commercialization efforts. This strategic partnership highlights the potential of RNA-based therapies in addressing significant unmet medical needs.<\/p>\n\n\n\n

Financial Terms<\/strong>
If Lilly exercises all available options under the agreement, the total deal value could exceed USD 1.3 billion. Additionally, Rznomics will be eligible to receive separate royalties on product sales. This collaboration underscores Rznomics’ innovative capabilities and positions both companies at the forefront of RNA-based therapeutic development.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration…<\/p>\n","protected":false},"author":1,"featured_media":33600,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,66,911,4076],"class_list":["post-33598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eli-lilly","tag-gene-therapy","tag-nyse-lly","tag-rznomics"],"yoast_head":"\nRznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics' proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33598\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss\" \/>\n<meta property=\"og:description\" content=\"South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics' proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33598\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T05:00:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss\",\"datePublished\":\"2025-05-16T05:00:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1608.webp\",\"keywords\":[\"Eli Lilly\",\"Gene therapy\",\"NYSE: LLY\",\"Rznomics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33598#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33598\",\"name\":\"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1608.webp\",\"datePublished\":\"2025-05-16T05:00:22+00:00\",\"description\":\"South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics' proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33598\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1608.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1608.webp\",\"width\":1080,\"height\":608,\"caption\":\"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33598#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss - Insight, China's Pharmaceutical Industry","description":"South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics' proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33598","og_locale":"en_US","og_type":"article","og_title":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss","og_description":"South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics' proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.","og_url":"https:\/\/flcube.com\/?p=33598","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-16T05:00:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33598#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33598"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss","datePublished":"2025-05-16T05:00:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33598"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33598#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp","keywords":["Eli Lilly","Gene therapy","NYSE: LLY","Rznomics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33598#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33598","url":"https:\/\/flcube.com\/?p=33598","name":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33598#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33598#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp","datePublished":"2025-05-16T05:00:22+00:00","description":"South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration and licensing agreement with US pharmaceutical major Eli Lilly & Co. (NYSE: LLY). The partnership aims to utilize Rznomics' proprietary trans-splicing ribozyme platform to develop and commercialize novel RNA-editing therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33598#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33598"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33598#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp","width":1080,"height":608,"caption":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33598#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1608.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33598"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33598\/revisions"}],"predecessor-version":[{"id":33601,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33598\/revisions\/33601"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33600"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}